EPO, short for erythropoietin, is a hormone your kidneys produce that tells your bone marrow to make red blood cells. It acts as the body’s built-in oxygen sensor: when oxygen levels in your blood drop, your kidneys ramp up EPO production, and when oxygen is sufficient, they dial it back. This simple feedback loop keeps your red blood cell count in a healthy range. EPO is also manufactured synthetically as a medication to treat severe anemia, and it has a well-known history as a banned performance-enhancing substance in sports.
How EPO Works in Your Body
Specialized cells in your kidneys constantly monitor oxygen levels in your blood. When they detect a dip, they release EPO into the bloodstream. The hormone travels to your bone marrow, where it locks onto receptors on immature red blood cells. Without EPO, many of these young cells would die off through a natural process of programmed cell death. EPO essentially acts as a survival signal, keeping those precursor cells alive long enough to mature into fully functional red blood cells that can carry oxygen throughout the body.
Once oxygen delivery returns to normal, the kidney cells sense the change and slow EPO production. This negative feedback cycle keeps your red blood cell count remarkably stable under normal conditions. A small amount of EPO is also produced by the liver, but the kidneys handle the vast majority of the work.
Normal EPO Levels
A standard blood test can measure the amount of EPO circulating in your system. The typical reference range for healthy adults is 2.6 to 18.5 milliunits per milliliter (mU/mL), though labs may vary slightly. Levels outside this range can point to underlying problems. Abnormally high EPO often signals that the body is struggling to get enough oxygen to tissues, which can happen with lung disease, heart failure, or living at very high altitudes. Abnormally low EPO is commonly seen in kidney disease, since damaged kidneys lose their ability to produce the hormone.
Medical Uses of Synthetic EPO
In the 1980s, scientists used genetic engineering to create a synthetic version of EPO, opening the door to treating several types of anemia. The synthetic form is injected either under the skin or directly into a vein, typically three times per week or once weekly depending on the condition being treated.
The main conditions it’s approved for include:
- Chronic kidney disease. When failing kidneys can’t produce enough natural EPO, red blood cell counts fall and patients develop persistent anemia. Synthetic EPO replaces what the kidneys can no longer make, often allowing patients on dialysis to avoid frequent blood transfusions.
- Chemotherapy-related anemia. Many cancer treatments suppress the bone marrow, dropping red blood cell counts significantly. EPO helps the marrow recover faster in patients with non-bone marrow cancers.
- Surgery preparation. Some patients receive EPO in the weeks before elective surgery to build up their red blood cell reserves, reducing the need for donated blood during the procedure.
- HIV-related anemia. Certain antiviral medications can suppress red blood cell production, and EPO can help counteract that effect.
Risks and Side Effects
Synthetic EPO is not without risks, particularly when used aggressively to push red blood cell levels higher than necessary. The most common side effect is high blood pressure, occurring in roughly 10% to 15% of patients. This appears to happen because EPO increases the responsiveness of blood vessels to compounds that cause them to constrict, while simultaneously blunting the action of compounds that relax them. The result is higher vascular resistance and elevated blood pressure.
There was an early assumption that thicker blood (from having more red blood cells) was the primary driver of this blood pressure increase, but research has complicated that picture. In one study of hemodialysis patients treated with EPO for over a year, all 13 patients developed thicker blood, yet only three developed hypertension. Other research found that blood pressure rose well before any measurable change in blood thickness, suggesting the two effects are largely independent.
Beyond hypertension, pushing hemoglobin levels too high with EPO increases the risk of blood clots, stroke, and other cardiovascular events. This is why medical use involves regular blood monitoring to keep red blood cell levels within a safe target range rather than maximizing them.
EPO in Sports and Doping
EPO became infamous in endurance sports, particularly professional cycling, during the 1990s and 2000s. The logic is straightforward: more red blood cells means more oxygen delivered to working muscles, which translates to better endurance performance. For an athlete, injecting EPO produces the same physiological benefit as training at high altitude for weeks, but without the time or effort.
The danger for athletes is the same as for patients, only amplified. Athletes using EPO without medical supervision often push their red blood cell counts far beyond normal, dramatically increasing blood viscosity. Combined with the dehydration that comes with intense exercise, this creates a serious risk of blood clots, heart attack, and stroke. Several unexplained deaths among young endurance athletes in the late 1980s and 1990s were widely attributed to EPO abuse, though definitive proof in individual cases was difficult to establish.
The World Anti-Doping Agency (WADA) has banned EPO since the early 2000s and has developed increasingly sophisticated detection methods. Current testing uses a technique called polyacrylamide gel electrophoresis, which separates proteins by their electrical charge and molecular weight. Synthetic EPO has a slightly different structure than the natural version, producing a distinct banding pattern on the gel. Labs first run an initial screening test, and if the result looks suspicious, they perform a confirmation test using a different gel method. Mass spectrometry, which identifies molecules by their precise mass, is also approved as an alternative detection tool. These methods can distinguish synthetic EPO from the body’s own supply, making it far harder for athletes to use the drug undetected than it was two decades ago.